CVS Health (NYSE:CVS - Get Free Report) had its price target lowered by UBS Group from $71.00 to $67.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "neutral" rating on the pharmacy operator's stock. UBS Group's price objective points to a potential upside of 10.43% from the stock's previous close.
Other equities analysts also recently issued research reports about the company. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $84.00 target price (up previously from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Royal Bank Of Canada upped their target price on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. Robert W. Baird upped their target price on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research report on Tuesday, April 15th. Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Finally, Cowen reaffirmed a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, CVS Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.82.
View Our Latest Analysis on CVS
CVS Health Stock Performance
NYSE:CVS traded up $1.92 on Tuesday, hitting $60.67. The company's stock had a trading volume of 10,876,618 shares, compared to its average volume of 10,020,364. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The stock has a fifty day moving average of $64.65 and a two-hundred day moving average of $63.31. The firm has a market capitalization of $76.75 billion, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57. CVS Health has a one year low of $43.56 and a one year high of $72.51.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.31 earnings per share. Research analysts predict that CVS Health will post 5.89 earnings per share for the current year.
Insider Activity at CVS Health
In other news, Director Guy P. Sansone purchased 1,570 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the purchase, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.22% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of CVS. Bell Investment Advisors Inc lifted its stake in shares of CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after acquiring an additional 248 shares during the last quarter. McIlrath & Eck LLC lifted its stake in shares of CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after acquiring an additional 174 shares during the last quarter. Roxbury Financial LLC lifted its stake in shares of CVS Health by 78.3% in the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock valued at $32,000 after acquiring an additional 202 shares during the last quarter. ORG Partners LLC lifted its stake in shares of CVS Health by 418.9% in the 2nd quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator's stock valued at $32,000 after acquiring an additional 377 shares during the last quarter. Finally, Saudi Central Bank bought a new position in CVS Health during the 1st quarter worth $34,000. 80.66% of the stock is currently owned by institutional investors.
About CVS Health
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
